Global Survey Reveals Significant Burden and Inconsistent Management of Rare Metabolic Bone Disorder in Adults

Why It Matters

The findings expose critical gaps in diagnosis and treatment of a rare, debilitating bone disease, prompting health systems to standardise care pathways and improve patient outcomes globally.

Key Takeaways

• Adults with HO report chronic bone pain, muscle weakness, reduced work capacity.
• XLH patients often stop phosphate/vit D, some start burosumab.
• TIO patients mainly receive phosphate/vit D; burosumab use remains limited.
• Pain medication, including opioids, is widely prescribed across HO subtypes.
• Management varies by geography and specialist access, exposing care gaps.

Pulse Analysis

The survey underscores how rare metabolic bone disorders like hypophosphatemic osteomalacia remain under‑recognized despite their profound impact on adult patients. Chronic bone pain, muscle weakness and reduced work capacity translate into lost productivity and heightened health‑care utilization, yet many primary‑care physicians encounter these conditions only sporadically. Delayed diagnosis is compounded by the transition from paediatric to adult services, where expertise often fragments, leaving patients to navigate a maze of specialists without a clear treatment roadmap.

Therapeutic options for HO are evolving. Traditional phosphate and active vitamin D supplementation remain the backbone for tumour‑induced osteomalacia, while the monoclonal antibody burosumab is gaining traction for X‑linked hypophosphatemia, though adherence gaps persist. Opioid and other analgesic prescriptions are common, reflecting inadequate pain control across subtypes. Geographic disparities in drug availability, reimbursement policies and specialist density drive the observed heterogeneity in care, highlighting the need for harmonised clinical guidelines that accommodate regional realities.

From a strategic perspective, the study’s global lens offers a template for collaborative rare‑disease research. By leveraging the IOF network, stakeholders can identify systemic weaknesses, prioritize education for primary‑care clinicians, and foster multidisciplinary teams that include endocrinologists, rheumatologists and orthopaedic surgeons. Future investigations should quantify economic burdens, assess long‑term outcomes of emerging therapies, and develop patient‑centred metrics that capture quality‑of‑life improvements. Aligning policy, research and clinical practice will be essential to transform the current patchwork of HO management into a cohesive, evidence‑based standard of care.